Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company

Stock Information for Scopus BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scopus BioPharma Inc.

Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary - Duet BioTherapeutics - to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
Scopus BioPharma's Subsidiary - Duet BioTherapeutics - to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Scopus BioPharma Provides Update Following Annual Meeting of Stockholders
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.